Biotechnology company Infinimmune has closed a $12 million seed round to focus on human-derived antibody drugs.
The seed funding was led by Playground Global, with participation from Pear VC, Civilization Ventures, Axial VC, Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier.
“The industry has proven the value of antibody-based drugs, but the limited number of both drugs and targets demonstrates a need for new approaches to discovery,” said Wyatt McDonnell, CEO and Co-founder of Infinimmune.
“We aim to take full advantage of truly human antibodies, identifying better and safer drug candidates more efficiently. We’re thrilled that this world-class group of investors shares our vision, and we are excited to expand our team, develop our R&D capabilities, and scale our operations.”
Infinimmune founders Wyatt McDonnell, Katie Pfeiffer, Mike Gibbons, Lance Hepler, and David Jaffe have led development teams at 10x Genomics, Pacific Biosciences, and the Broad Institute.